Hence, the target molecules like iNKT cells, IL-18, anti-CD1d or anti-Vα24/Jα18 antibodies can be utilized for the future diagnosis and therapeutic treatment strategies for EGID. This evidence concerns the gene IL18 and eosinophilic gastrointestinal disease.